Methods For Treating Diseases Using Isoindoline Compounds

Patent No. EP3320902 (titled "Methods For Treating Diseases Using Isoindoline Compounds") was filed by Amgen Europe on Mar 2, 2012. The application was issued on Feb 17, 2021.

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

Company	Opposition Date	Representative
TEVA PHARMACEUTICALS	Nov 16, 2021	D YOUNG

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

Date
Description

Get instant alerts for new documents

Jul 22, 2022
Communication to the parties concerning the termination of the opposition proceedings (opponent)
Jul 22, 2022
Communication to the parties concerning the termination of the opposition proceedings (proprietor)
Jul 19, 2022
Termination of the opposition proceedings with revocation of patent
Apr 21, 2022
(Electronic) Receipt
Apr 21, 2022
Advice of delivery
Apr 21, 2022
Letter accompanying subsequently filed items
Apr 7, 2022
Decision revoking the European patent
Apr 7, 2022
Decision revoking the European patent
Apr 7, 2022
Transmittal of decision / summons - opposition
Apr 7, 2022
Transmittal of decision / summons - opposition
Mar 28, 2022
(Electronic) Receipt
Mar 28, 2022
Letter accompanying subsequently filed items
Mar 28, 2022
Request for revocation of patent
Dec 1, 2021
Communication of a notice of opposition and request to file observations
Dec 1, 2021
Notice of further oppositions to opponent(s)
Nov 22, 2021
Communication of a notice of opposition - first information to patent proprietor
Nov 16, 2021
(Electronic) Receipt
Nov 16, 2021
Citation in opposition procedure - 001
Nov 16, 2021
Consolidated list of cited opposition documents
Nov 16, 2021
Notice of opposition
Nov 16, 2021
Notice of opposition
Mar 1, 2021
Transmission of the certificate for a European patent pursuant to Rule 74 EPC
Jan 21, 2021
Decision to grant a European patent
Jan 11, 2021
(Electronic) Receipt
Jan 11, 2021
Filing of the translations of the claims
Jan 11, 2021
French translation of claims
Jan 11, 2021
German translation of the claims
Jan 11, 2021
Letter accompanying subsequently filed items
Sep 3, 2020
Bibliographic data of the European patent application
Sep 3, 2020
Communication about intention to grant a European patent
Sep 3, 2020
Intention to grant (signatures)
Sep 3, 2020
Text intended for grant (clean copy)
Sep 3, 2020
Text intended for grant (sequence listing)
Sep 3, 2020
Text intended for grant (version for approval)
Jul 15, 2020
Examination started
Mar 23, 2020
Communication of the registration of a transfer or change of name and/or address
Mar 10, 2020
Annexes in respect of a client data request
Mar 10, 2020
Submission concerning a transfer of rights (applicant)
Mar 10, 2020
Submission concerning a transfer of rights (applicant)
Jan 21, 2020
Communication of amended entries concerning the representative
Dec 23, 2019
Letter accompanying subsequently filed items
Dec 23, 2019
Submission concerning change of applicant's representative
Nov 16, 2018
(Electronic) Receipt
Nov 16, 2018
Amended description filed after receipt of (European) search report
Nov 16, 2018
Amendments received before examination
Nov 16, 2018
Letter accompanying subsequently filed items
Nov 16, 2018
Letter filed before dispatch of the 1st communication from the Examining Division(examination procedure)
May 22, 2018
Reminder period for payment of examination fee/designation fee and correction of deficiencies in Written Opinion/amendment
Apr 18, 2018
Notification of forthcoming publication
Apr 18, 2018
Refund of fees
Apr 5, 2018
Refund of fees
Mar 27, 2018
Communication regarding the transmission of the European search report
Mar 27, 2018
European search opinion
Mar 27, 2018
European search report
Mar 27, 2018
Information on Search Strategy
Mar 19, 2018
Search started
Mar 13, 2018
(Electronic) Receipt
Mar 13, 2018
Letter concerning fees and payments
Feb 9, 2018
Communication to designated inventor
Feb 9, 2018
Communication to designated inventor
Jan 22, 2018
(Electronic) Receipt
Jan 22, 2018
Designation of inventor
Jan 22, 2018
Letter accompanying subsequently filed items
Jan 22, 2018
Letter concerning the inventor
Jan 12, 2018
Deficiency in designation of inventor
Dec 18, 2017
Abstract
Dec 18, 2017
Acknowledgement of receipt of electronic submission of the request for grant of a European patent
Dec 18, 2017
Claims
Dec 18, 2017
Converted Sequence Listing
Dec 18, 2017
Description
Dec 18, 2017
Drawings
Dec 18, 2017
Request for grant of a European patent
Oct 3, 2012
Priority document
Oct 3, 2012
Priority document (electronically transmitted)

EP3320902

AMGEN EUROPE

Application Number: EP17208060A
Filing Date: Mar 2, 2012
Status: Revoked; Jul 22, 2022
Publication Date: Feb 17, 2021
External Links: Slate, Register , Google Patents

IP Verse

Methods For Treating Diseases Using Isoindoline Compounds

Patent Summary

Patent Family

Patent Oppositions

Dossier Documents

EP3320902